세계 이식편대숙주병(GvHD) 시장 규모는 2024년부터 2031년까지 예측 기간 동안 연평균 9.51%의 CAGR로 2023년 29억 9,000만 달러에서 2031년에는 61억 9,000만 달러 규모로 성장할 것으로 예상됩니다.
GvHD 시장은 장기 이식 및 줄기세포 이식과 같은 이식 수요 증가, 기술 발전, 정부 이니셔티브, AI 통합 등의 요인으로 인해 성장하고 있습니다. 이식 수요의 증가는 GvHD의 유병률을 높이고 치료 옵션에 대한 수요를 가속화하고 있습니다. 환자들은 이식 후 나타나는 증상에 대처할 수 있는 보다 신뢰할 수 있고 번거롭지 않은 최선의 방법을 찾고 있습니다. 또한, 정부도 최고의 기술을 시장에 출시하기 위해 R&D에 많은 자금을 투자하고 있습니다. 많은 새로운 발전은 이식 수술을 받은 환자의 회복을 더 빠르고 더 좋게 하는 데 도움이 되고 있습니다.
GvHD의 유병률 상승
GvHD 시장은 줄기세포 이식의 증가로 인해 크게 성장하고 있습니다. 줄기세포 이식은 여러 면역학 및 혈액학 문제를 치료할 수 있는 강력한 새로운 방법입니다. 그러나 이식 수술이 증가함에 따라 GvHD의 유병률도 증가하고 있습니다. 줄기세포 이식은 다양한 질병에 대한 일반적인 치료법이 되었습니다. 환자의 줄기세포를 이용한 자가 이식과 공여자의 줄기세포를 이용한 동종 이식이 있습니다. 재생불량성 빈혈, 중증복합면역결핍증(SCID)과 같은 비악성 질환과 백혈병, 림프종, 골수종과 같은 혈액학적 악성종양 치료는 모두 줄기세포 이식의 혜택을 받고 있습니다. 줄기세포 이식을 받는 사람들이 늘어남에 따라 GvHD 발병 위험도 증가하고 있습니다. 의사와 연구자들은 기존 용도 외에도 고형 장기 이식 지원, 자가면역질환 이식, 재생의료에 대한 적응증을 연구하고 있습니다. 이식 수술의 다양화로 인해 GvHD 발병 위험이 있는 환자군이 확대됨에 따라 효율적인 GvHD 치료에 대한 수요는 더욱 증가하고 있습니다.
정부의 노력
GvHD 치료제의 제조 및 승인을 위한 규제 당국의 지속적인 지원은 시장 성장의 주요 촉진요인 중 하나이며, GvHD에 대한 조사, 임상 연구 및 유망한 의약품의 상업화는 정부 및 민간 부문의 막대한 자금 지원을 받고 있습니다. 정부는 이 분야를 다루는 연구 센터, 의료 전문가 및 연구 기관과 협력하는 이니셔티브를 취하고 있습니다.
기술의 발전
GvHD의 치료 기술은 놀라운 속도로 확장되고 있는데, 그 주요 이유는 의료 기술의 발전으로 인해 GvHD의 진단 능력이 크게 향상되었습니다. 게놈 시퀀싱, 바이오마커 식별, 고해상도 영상 진단을 통해 의료진은 GvHD를 높은 정확도로 감지할 수 있습니다. 의료 기술의 발전으로 GvHD 환자의 필요에 맞게 특별히 고안된 표적 치료가 가능해졌으며, GvHD에 대한 유망한 치료법으로는 면역 조절제, 생물학적 제제, 단클론항체 등이 있습니다. 이러한 면역학적 프로파일에 따라 정밀하게 조정된 의약품은 더 적은 해를 끼치면서 질병을 더 잘 조절할 수 있는 수단을 제공합니다.
세계 이식편대숙주병(GvHD) 시장을 조사했으며, 시장 정의와 개요, 시장 규모 추이 및 예측, 각종 부문별·지역별 상세 분석, 산업 구조, 시장 성장에 영향을 미치는 요인 분석, 사례 연구, 경쟁 구도, 주요 기업 개요 등의 정보를 전해드립니다.
Global graft versus host disease market is projected to witness a CAGR of 9.51% during the forecast period 2024-2031, growing from USD 2.99 billion in 2023 to USD 6.19 billion in 2031. The graft versus host disease (GvHD) market is experiencing growth due to factors such as rising demand for transplants, such as organ transplants or stem cell transplants, advancements in technology, government initiatives, and the integration of AI. Increasing demand for transplantations has boosted the prevalence of GvHD, which, in turn, has accelerated the demand for treatment options. Patients are looking for a more reliable, hassle-free, and best possible approach to deal with the symptoms that come after the transplantations. Furthermore, the government is also spending significant amounts on research and development to bring out the best possible techniques in the market. Many new advancements are helping faster and better recovery of patients after undergoing transplantation procedures.
Results from a phase 2 study (NCT02867384) presented during the 2023 ASH Annual Meeting showed that using obinutuzumab (Gazyva) to enhance B-cell depletion significantly reduced the need for corticosteroids and increased relapse-free survival in patients with steroid-requiring chronic GvHD undergoing well-matched hematopoietic stem cell transplant.
Rising Prevalence of GvHD
The market for GvHD is expanding significantly due to the rising use of stem cell transplants. A potent new technique for treating several immunological and hematological problems is stem cell transplantation. However, the prevalence of GvHD has increased in tandem with the growth in transplant procedures. Stem cell transplants have become a common therapy option for a variety of illnesses. They can be performed autologously, using the patient's stem cells, or allogeneically, using donor stem cells. Treatments for non-malignant conditions, including aplastic anemia and severe combined immunodeficiency (SCID), as well as hematological malignancies like leukemia, lymphoma, and myeloma, are both benefiting from this rising use. There is a growing risk of developing GvHD as more individuals receive stem cell transplantation. Beyond the conventional applications, physicians and researchers are investigating solid organ transplant support, autoimmune disease transplantation, and regenerative medicine applications. The demand for efficient GvHD treatments is being further driven by the expansion of the patient pool at risk of developing GvHD due to the diversity of transplant procedures.
In the United States, 42% of patients had developed chronic (cGvHD) within three years following allogenic HCT; 66% of those impacted by cGvHD had acute GvHD prior, per an Elsevier paper from June 2021.
Government Initiatives
Ongoing support by regulatory bodies toward the production and approval of GvHD medicines is acting as one of the main market drivers of flourishing growth. Research, clinical studies, and the commercialization of promising medicines related to GvHD are receiving significant funding from the government and private sectors. The government is taking initiatives to collaborate with research centers, healthcare professionals, and institutes that deal with this sector. According to the Australian government's Department of Health and Aged Care, new medications are now available for treating esophageal cancer, chronic rhinosinusitis, and GvHD. The new and upgraded medications, which will be covered under the Pharmaceutical Benefits Scheme (PBS), include Opdivo (nivolumab), Jakavi (ruxolitinib), and Nucala (mepolizumab).
Technological Advancements
The treatment techniques for GvHD are expanding at an impressive rate, mostly due to the ongoing progress in medical technology. The ability to diagnose GvHD has greatly improved due to developments in healthcare technologies. Using genome sequencing, biomarker identification, and high-resolution imaging, medical professionals can detect GvHD with high accuracy. Early detection is essential because it enables timely action, which may stop the illness from getting worse. Targeted therapies that are specifically designed to meet the needs of patients with GvHD are now possible due to advancements in medical technology. Promising therapies for GvHD include immunomodulatory medications, biologics, and monoclonal antibodies. These precisely tailored immunological profile-based medicines provide a less harmful and more successful means of controlling the illness.
The development of cellular and gene treatments is one of the biggest developments in the treatment of GvHD. GvHD may be treated with chimeric antigen receptor T-cell (CAR-T) therapy, which targets the immune cells that cause the illness. CRISPR-Cas9 and other gene editing methods show promise for precisely modifying immune cells to prevent or treat GvHD. Innovative medical technology makes these state-of-the-art treatments possible. Treatment has been transformed by the combination of telemedicine and remote monitoring technology, especially when it comes to GvHD. Improved GvHD management and patient outcomes are a result of this accessibility, which also improves patient compliance and overall quality of care. Big data analytics and artificial intelligence (Al) are being utilized to help with GvHD early detection and prevention. Large-scale datasets can be analyzed by machine learning algorithms, which can then spot patterns and risk factors that human clinicians could miss. With the use of this technology, medical professionals can anticipate future GvHD consequences, personalize treatment regimens, and make better decisions.
Research studies from Michigan Medicine, the Children's Hospital of Philadelphia, and Penn Medicine are paving the road for novel gene therapy treatments for blood disorders like sickle cell anemia. A patient still needs chemotherapy and the transplantation of their own corrected cells even after gene therapy corrects the mutation in their cells. However, it is possible to genetically modify blood stem cells in the bone marrow during a single therapy.
Corticosteroids are Dominating the Global Market
Tyrosine kinase inhibitors, corticosteroids, monoclonal antibodies, and other pharmaceuticals make up the product segment of this market. Due to the increasing number of research studies and the rising prevalence of the target disease, the corticosteroid segment retained the biggest share in 2023. Furthermore, the corticosteroid segment is anticipated to grow over the forecast period due to increased research and development efforts focused on corticosteroids and their combinations for the treatment of GvHD in patients undergoing hematopoietic cell transplantation (HCT). Corticosteroids help in managing the immune system and can also limit the activity of donated T-cells in the host's body. It even helps to reduce inflammation caused after the transplant, which regulates the blood pressure well. As of June 2022, an open-label, multicenter, two-arm randomized trial was conducted to evaluate the efficacy of corticosteroids alone or in combination with Ruxolitinib for newly identified high-risk acute gene therapy-related heart failure or dysfunction. It has been observed that roughly 50% of instances of acute graft-versus-host disease (aGvHD) respond to corticosteroid first-line therapy.
North America to Dominate GvHD Market
The North American region is expected to hold a significant market size due to its well-established healthcare infrastructure, ongoing research and development activities, and a growing number of transplant procedures. An increasing number of transplants performed in North America is accelerating market opportunities in the region. Between January 2022 and June 2022, 20,663 transplant procedures were performed in the United States, according to statistics provided by the Organ Procurement and Transplantation Network, which is supervised by the US Department of Health and Human Services and updated in July 2022. Due to the immunological-mediated reactions that take place between the recipients' and donors' adaptive immune systems, the rise in transplant cases may raise demand for therapies for GvHD, which would ultimately spur market demand.
Future Market Scenario (2024 - 2031F)
The growing need to address a variety of symptoms that occur post transplantation processes can fuel the market of GvHD. Increasing number of organ transplantations and the use of new types of inhibitors are also driving market expansion.
The advent of new and improved technologies, well researched drugs, gene editing techniques, and the integration of AI have enabled high accuracy and precision, which, in turn, is anticipated to increase market share in the upcoming years.
Personalised treatment strategies that target genetic alterations and pathways are becoming more and more popular as precision medicine gains traction. AI has also enhanced early detection for any possible indications that further helps the treatment as well as ensure market expansion.
Global regulatory bodies are building frameworks to speed up the development of specialized transplantation departments, which is also driving the expansion of the GvHD market worldwide.
Key Players Landscape and Outlook
There are several significant players in the competitive graft versus host disease market. Currently, the market is dominated by a few dominant players, such as Merck & Co., Inc, Novartis AG, Astellas Pharma Inc., Astra Zeneca PLC, Bayer AG, Boehringer Ingelheim International Gmbh, Abott Inc., Bristol Myers Squibb, Pfizer Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Elli Lilly and Company, etc. These companies are governing the market share because of their consistent efforts toward R&D, technological advancements, and reliable quality.
Jakavi (ruxolitinib), approved by the European Commission (EC) in May 2022, is intended to treat individuals with acute or chronic GvHD who are 12 years of age or older and do not respond well to corticosteroids or other systemic therapy.
The EQUATOR project, a major Phase III clinical trial of itolizumab in patients with aGvHD, was started by Equillium Inc. in March 2022. When used in conjunction with corticosteroids, itolizumab versus placebo will be evaluated for both safety and efficacy as first-line therapy for aGvHD in this randomized, double-blind study.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.